Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.399
Filter
1.
Medisan ; 26(5)sept.-oct. 2022. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1405839

ABSTRACT

Introducción: La duodenopancreatectomía cefálica continúa siendo una intervención quirúrgica compleja. Objetivo: Caracterizar a los pacientes operados de duodenopancreatectomía cefálica según variables epidemiológicas, clínicas e histológicas seleccionadas. Métodos: Se realizó un estudio observacional, descriptivo y retrospectivo de una serie de 15 casos operados de duodenopancreatectomía cefálica en el Servicio de Cirugía General del Hospital Provincial Docente Saturnino Lora de Santiago de Cuba, durante el quinquenio 2016-2020. Las variables analizadas fueron edad, sexo, comorbilidades, hábitos tóxicos, síntomas y signos, así como tipo histológico de las lesiones. Resultados: Predominaron los pacientes del sexo masculino (80,0 %) y el grupo de 50 a 55 años de edad (40,0 %). Las comorbilidades más frecuentes fueron la hipertensión arterial en 80,0 % de la casuística, seguida de la diabetes mellitus en 53,3 %. Prevalecieron el tabaquismo (66,7 %) y el alcoholismo (60,0 %), así como los signos de obstrucción biliar (73,3 %). El diagnóstico histológico principal fue adenocarcinoma de páncreas en 60,1 % de los afectados. Conclusiones: La duodenopancreatectomía cefálica se realiza predominantemente en pacientes con adenocarcinomas de páncreas y, en menor medida, con adenocarcinomas de duodeno y otras afecciones benignas; en afectados del sexo masculino, con edades intermedias y avanzadas de la vida, hipertensión arterial y diabetes mellitus, así como tiempo prolongado de ser fumadores y consumidores de alcohol. Los signos de obstrucción biliar son de importancia capital en el diagnóstico clínico.


Introduction: The cephalic pancreaticoduodenectomy continues being a complex surgical intervention. Objective: To characterize patients operated on cephalic duodenopancreatectomy according to selected epidemiological, clinical and histologic variables. Methods: An observational, descriptive and retrospective study of a series of 15 cases operated on cephalic pancreaticoduodenectomy was carried out in the General Surgery Service of Saturnino Lora Teaching Provincial Hospital in Santiago de Cuba, during the five year period 2016-2020. The analyzed variables were age, sex, comorbidities, toxic habits, symptoms and signs, as well as histologic type of the lesions. Results: There was a prevalence of the male sex patients (80.0 %) and the 50 to 55 age group (40.0 %). The most frequent comorbidities were hypertension in 80.0 % of the case material, followed by the diabetes mellitus in 53.3 %. Nicotine addiction (66.7 %) and alcoholism (60.0 %) prevailed, as well as the signs of biliary obstruction (73.3 %). The main histologic diagnosis was pancreas adenocarcinoma in 60.1 % of those affected. Conclusions: The cephalic pancreaticoduodenectomy is carried out predominantly in patients with pancreas adenocarcinomas and, to a lesser extent, in patients with duodenum adenocarcinomas and other benign affections; in those affected of the male sex, with intermediate and advanced ages of life, hypertension and diabetes mellitus, as well as long time of being smokers and alcohol consumers. The signs of biliary obstruction are of capital importance in the clinical diagnosis.


Subject(s)
Pancreatic Neoplasms , Pancreaticoduodenectomy
2.
Rev. cir. (Impr.) ; 74(4): 339-344, ago. 2022. tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1407935

ABSTRACT

Resumen Introducción: Los tumores periampulares se definen como lesiones ubicadas en un radio de 2 cm alrededor de la ampolla de Vater, constituidos por 4 tipos de neoplasias con una alta tasa de malignidad que pueden originarse en páncreas, ampolla, vía biliar distal o duodeno. El manejo quirúrgico a través de la pancreatoduodenectomía sigue siendo la mejor elección en términos de resección curativa. Objetivo: Caracterizar los tumores peri-ampulares tratados en nuestra institución y que fueron llevados a pancreatoduodenectomía, asociando la relación entre tipo de tumor y complicaciones posoperatorias. Material y Método: Estudio transversal, retrospectivo y observacional con seguimiento a 45 pacientes sometidos a pancreatoduodenectomía en el Hospital Internacional de Colombia - Fundación Cardiovascular entre enero de 2011 y marzo de 2020 con diagnostico histopatológico de tumor peri-ampular. Resultados: Se realizaron 75 pancreatoduodenectomía de las cuales 45 pacientes presentaron tumor peri-ampular, siendo de origen pancreático en un 44%, seguido de ampolla 40%, vía biliar distal 8,8% y duodenal 6,6%. Las complicaciones posoperatorias más frecuentes fueron fístula pancreática y vaciamiento gástrico retardado. Falleció 1 paciente. Conclusión: La pancreatoduodenectomía es un procedimiento con alta morbilidad. Gracias al avance tecnológico, el diagnóstico de patología peri ampular es cada vez más exacto. El tipo de tumor peri-ampular puede influir no solo en su pronóstico, sino también en su morbilidad posquirúrgica.


Introduction: Periampullary tumors are defined as lesions that are located in a radius of 2 centimeters around the ampulla of Vater, constituted by 4 types of neoplasms with a high rate of malignancy originated in the pancreas, ampulla, distal bile duct or duodenum. Surgical management through the pancreatoduodenectomy remains the best choice in terms of curative resection. Objetive: To characterize periampullary tumors treated in our institution with pancreatoduodenectomy, associating the relationship between tumor type and postoperative complications. Material and Method: Cross-sectional, retrospective, observational study with a follow-up of 45 patients underwent pancreatoduodenectomy in the Hospital Internacional de Colombia - Fundación Cardiovascular between January 2011 and March 2020 with histopathological diagnosis of periampullary tumor. Results: Were performed 75 pancreatoduodenectomies, 45 patients presented with Periampullary tumor, 44% being of pancreatic origin, followed by ampulla 40%, distal bile duct 8.8% and duodenal 6.6%. Most frequent postoperative complications were pancreatic fistula and delayed gastric emptying. Mortality was of 1 patient. Conclusión: Pancreatoduodenectomy is a procedure with a high morbidity rate. Thanks to technological advances, the diagnosis of periampullary pathology is increasingly accurate. The type of periampullary tumor may influence not only in its prognosis, but also in its post-surgical morbidity.


Subject(s)
Humans , Male , Female , Pancreatic Neoplasms/surgery , Laparoscopy , Abdominal Neoplasms/surgery , Pancreatectomy/adverse effects , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Postoperative Complications/epidemiology , Cross-Sectional Studies , Retrospective Studies , Pancreaticoduodenectomy/adverse effects
3.
Medisan ; 26(4)jul.-ago. 2022. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1405822

ABSTRACT

Introducción: El cáncer de páncreas constituye una de las neoplasias de peor pronóstico debido a su diagnóstico tardío. Objetivo: Caracterizar a los pacientes con cáncer de páncreas según variables clinicoepidemiológicas y exámenes complementarios. Métodos: Se realizó un estudio observacional, descriptivo y transversal de 70 pacientes con cáncer de páncreas, egresados del Servicio de Cirugía General del Hospital Provincial Docente Saturnino Lora de Santiago de Cuba durante el periodo 2016-2020. Se estudiaron las variables: edad, sexo, factores de riesgo, enfermedades asociadas, manifestaciones clínicas y exámenes complementarios. Resultados: Predominaron el sexo masculino ( 54,2 %), las edades comprendidas de entre 51- 70 años, la ingestión de comidas grasas y los hábitos tabáquico y alcohólico como factores de riesgo; el alcoholismo crónico, la diabetes mellitus y la hipertensión arterial como enfermedades asociadas más comunes, así como el síndrome general, la ictericia y la coluria entre las manifestaciones clínicas más frecuentes. Por su parte, según los estudios imagenológicos, la mayoría de los afectados se diagnosticaron mediante tomografía computarizada y ecografía abdominal (94,3 y 70,0 %, respectivamente). Conclusiones: La tomografía computarizada multicorte es la técnica de imagen de elección recomendada por las guías de consenso internacional. Si bien el informe radiográfico es clave para la toma de decisiones posteriores, existen circunstancias del paciente que pueden afectarlas, tales como edad, factores de riesgo, manifestaciones clínicas y comorbilidad, entre otras.


Introduction: The pancreas cancer constitutes one of the neoplasms with worse prognosis due to its late diagnosis. Objective: To characterize patients with pancreas cancer according to clinical epidemiological variables and complementary exams. Methods: An observational, descriptive and cross-sectional study of 70 patients with pancreas cancer was carried out, who were discharged from the General Surgery Service of Saturnino Lora Teaching Provincial Hospital in Santiago de Cuba during 2016-2020. The variables studied were: age, sex, risk factors, associated diseases, signs and symptoms and complementary exams. Results: There was a prevalence of the male sex (54.2 %), the 51-70 age group, the ingestion of fatty foods and nicotine addiction and alcoholism as risk factors, the chronic alcoholism, diabetes mellitus and hypertension as more common associated diseases, as well as the general syndrome, jaundice and coluria among the most frequent signs and symptoms. On the other hand, according to the imaging studies, most of those affected were diagnosed by means of computerized axial tomography and abdominal echography (94.3 and 70.0 %, respectively). Conclusions: The multiscan computerized axial tomography is the image technique of election recommended by the guides of international consent. The radiographic report is the key for later decisions making but there are circumstances of the patient that can affect them, such as age, risk factors, signs and symptoms and comorbidity, among others.


Subject(s)
Pancreatic Neoplasms , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/epidemiology , Comorbidity
4.
J. health med. sci. (Print) ; 8(2): 99-104, abr.-jun. 2022. ilus, tab
Article in Spanish | LILACS | ID: biblio-1391919

ABSTRACT

Dentro de los cánceres, el tumor maligno de páncreas sigue siendo una neoplasia altamente letal y se tiene dificultad en el diagnóstico temprano, por lo que hay que evaluar de manera sistemática el comportamiento epidemiológico de esta enfermedad. OBJETIVO: determinar las características epidemiológicas del cáncer de páncreas de los pacientes atendidos en el hospital SOLCA Guayaquil, entre los años 2015 al 2021. MATERIALES Y MÉTODO: observacional, de diseño transversal, tipo descriptivo; en los pacientes vistos por primera vez con tumor maligno de páncreas atendidos en el hospital de SOLCA y que sean residentes de Guayaquil; excluyéndose los pacientes diagnosticados en otras instituciones. RESULTADOS: durante el período 2015-2021 el cáncer de páncreas se incrementó, del año 2015 con 4,8% al 2021 de 29,3%; es corroborado con la tendencia lineal con porcentaje de variabilidad del 81%; según sexo hubo un cambio en la presentación entre hombres y mujeres en la incidencia; más en mujeres con 56,9%. el grupo de edad mayormente afectado en ambos sexos fue de 50-70 años (76,6%); topográficamente el Tumor maligno de páncreas, parte no especificada fue del 49,7%, Tumor maligno de cabeza del páncreas con 27,5% y morfológicamente el adenocarcinoma SAI (31,7%) y adenocarcinoma del conducto SAI (11,4%). CONCLUSIÓN: el cáncer de páncreas viene incrementándose, con mayor proporción en mujeres entre 50-70 años de edad; topográficamente el Tumor maligno de páncreas, parte no especificada y morfológicamente el adenocarcinoma SAI fueron lo más frecuentes; por lo que se debe explorar métodos que permitan un diagnóstico temprano


Within cancers, malignant tumor of pancreas continues to be a lethal neoplasm and early diagnosis is difficult, for epidemiological behavior must be systematically evaluated. OBJECTIVE: determine the epidemiological characteristics of pancreatic cancer in patients treated at the SOLCA Guayaquil hospital, between 2015 and 2021. MATERIALS AND METHOD: observational, cross-sectional design, descriptive type; in patients seen for the first time with a malignant tumor of the pancreas treated at the SOLCA hospital and who are residents of Guayaquil; excluding patients diagnosed in other institutions. RESULTS: during the 2015-2021 period, pancreatic cancer increased, from 2015 with 4.8% to 2021 with 29.3%; it is corroborated with the linear trend with a percentage of variability of 81%; According to sex, there was a change in the presentation between men and women in the incidence; more in women with 56.9%. the most affected age group in both sexes was 50-70 years (76.6%); topographically, malignant tumor of the pancreas, part not specified was 49.7%, malignant tumor of the head of the pancreas with 27.5% and morphologically, adenocarcinoma SAI (31.7%) and duct adenocarcinoma SAI (11.4%). CONCLUSION: pancreatic cancer has been increasing, with a higher proportion in women between 50-70 years of age; topographically, malignant tumor of the pancreas, unspecified part and morphologically, adenocarcinoma SAI were the most frequent; Therefore, methods that allow an early diagnosis should be explored.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Pancreatic Neoplasms/epidemiology , Cancer Care Facilities/statistics & numerical data , Cross-Sectional Studies , Ecuador/epidemiology , Age and Sex Distribution
5.
Rev. colomb. gastroenterol ; 37(1): 10-23, Jan.-Mar. 2022. tab, graf
Article in Spanish | LILACS | ID: biblio-1376901

ABSTRACT

El ultrasonido endoscópico ha cambiado la evaluación de las enfermedades pancreáticas y ha logrado un diagnóstico histopatológico (cuando se asocia con la punción); sin embargo, este procedimiento requiere de entrenamiento, no está libre de complicaciones y alrededor de 25% de los pacientes puede tener falsos negativos. Por esto se ha implementado el uso de la elastografía cuantitativa con el strain ratio, el cual permite diferenciar las masas benignas de las malignas. Existe evidencia creciente, pero aún no conclusiva, dada la heterogeneidad de los resultados (sin consenso para su realización), por lo que es necesario desarrollar otros métodos, que permitan una mayor certeza diagnóstica, como el índice de fibrosis hepática (IFH) medido por ultrasonografía endoscópica, el cual tienen como base la inteligencia artificial, validado para el diagnóstico y el seguimiento de la fibrosis hepática. Nuestro grupo considera que se podría usar de la misma forma para valorar el parénquima pancreático. Objetivo: evaluar si el IFH puede diferenciar tres tipos diferentes de tejidos pancreáticos: páncreas normal, páncreas graso y cáncer de páncreas. Metodología: estudio prospectivo de corte transversal en un solo centro. Se incluyeron 66 pacientes mayores de 18 años, con indicación de ultrasonografía endoscópica. El grupo 1 fue de pacientes con indicación diferente a la enfermedad biliopancreática (55 pacientes). En este grupo se aplicó la escala de clasificación de páncreas graso por ultrasonografía endoscópica (USE), utilizando como referencia la ecogenicidad del bazo (previamente validada); este grupo se subdividió en uno con parénquima pancreático normal y en otro con páncreas graso. En el grupo 2 (11 pacientes) se incluyeron los pacientes llevados para el estudio de lesión sólida pancreática, con diagnóstico citológico positivo para carcinoma de páncreas. Como herramienta de recolección de datos se utilizó un formulario virtual de Google Drive, disponible con dirección acortada: shorturl.at/pIMWX, diligenciado antes y después del procedimiento por fellows de Gastroenterología, previamente entrenados para este fin. El IFH se tomó en el páncreas en tiempo real mediante un software suministrado por el fabricante (Hitachi-Noblus), en un período comprendido entre enero de 2019 y enero 2020. A todos los pacientes se les realizó una ecoendoscopia biliopancreática completa, con un ecoendoscopio Pentax lineal y procesador Hitachi-Noblus; luego se efectuó una elastografía cualitativa y una cuantitativa, la cual incluyó la medición del IFH. Resultados: en total se incluyeron 66 pacientes: 11 pacientes con diagnóstico confirmado por citología de cáncer de páncreas y 55 pacientes que se enviaron para ecoendoscopia por evaluación de otras patologías diferentes a la biliopancreática. El rango de edad fue de 23-89, media de 56,75 años. El antecedente más frecuente fue la esteatosis o esteatohepatitis (n = 14) (25,45%). La indicación para la realización del procedimiento más frecuente fue la lesión subepitelial (n = 29) (52,73 %). Los porcentajes de pacientes según los grados de ecogenicidad del páncreas fueron de grado I (n = 29) (52,73 %); grado II (n = 5) (9,09 %); grado III (n = 18) (32,73 %); grado IV (n = 3) (5,45 %). Se tomaron los grados I y II como páncreas normal, y los grado III y IV como páncreas graso. Estos se dividieron en n = 34 pacientes (61,82 %) para páncreas normal y n = 21 (38 %) para páncreas graso; es decir, que de acuerdo con la escala utilizada hay una prevalencia para páncreas graso de 38,18 %. Se realizó el IFH en los tres subgrupos diferentes: los considerados como ecoendoscópicamente normales, los clasificados como páncreas graso y los pacientes con diagnóstico de cáncer de páncreas confirmado por citología, tomado en el páncreas. El IFH para los tres diferentes grupos fueron, respectivamente, normal: IFH 2,60, rango 0,97-3,47 (IC 95 % 2,17-3,02); páncreas graso: IFH 3,87, rango 2-5,5 (IC 95 % 3,44-4,29); cáncer de páncreas: IFH 6,35, rango 5,8-7,8 (IC 95 % 5,92-6,77). Conclusiones: este es el primer estudio piloto que usa el IFH aplicado al parénquima pancreático, y se sugiere su utilidad para diferenciar, de manera no invasiva, el páncreas normal, el graso y el carcinoma de páncreas. Este hallazgo se debe confirmar en poblaciones más amplias y heterogéneas, con el fin de ser validado.


Abstract Endoscopic ultrasound has changed the evaluation of pancreatic diseases and has achieved a histopathological diagnosis (when associated with a puncture); however, this procedure requires training, is not free of complications, and around 25 % of patients may have false negatives. Therefore, quantitative elastography with the strain ratio has been implemented to differentiate benign masses from malignant ones. There is growing but not yet conclusive evidence, given the heterogeneity of the results (without consensus on its performance). It is necessary to develop other methods that allow for greater diagnostic certainty, such as the liver fibrosis index (LFI) measured by endoscopic ultrasonography. This method is based on artificial intelligence and validated for diagnosing and monitoring liver fibrosis. Our group considers that it could also be used to assess the pancreatic parenchyma. Aim: To evaluate whether the LFI can differentiate three types of pancreatic tissues: normal pancreas, fatty pancreas, and pancreatic cancer. Materials and methods: Prospective cross-sectional single-center study. We included sixty-six patients over 18 years of age with an indication for endoscopic ultrasonography. Group 1 consisted of patients with an indication other than the biliopancreatic disease (55 patients). The endoscopic ultrasonography (EUS) fatty pancreas classification scale was applied to this group, taking the echogenicity of the spleen (previously validated) as a reference; this group was subdivided into normal pancreatic parenchyma and fatty pancreas. Group 2 (11 patients) included those examined for solid pancreatic lesions with a positive cytological diagnosis of pancreatic carcinoma. We used a Google Form as a data collection tool, available with a shortened address (shorturl.at/pIMWX). It was filled out before and after the procedure by Gastroenterology fellows, previously trained for this purpose. The LFI was measured in the pancreas in real-time using software supplied by the manufacturer (Hitachi Noblus) between January 2019 and January 2020. All patients underwent a complete biliopancreatic echoendoscopy, with a linear Pentax echoendoscope and Hitachi Noblus processor. Then, qualitative and quantitative elastography was performed, including LFI measurement. Results: We included a total of 66 patients: 11 with a diagnosis of pancreatic cancer confirmed by cytology and 55 sent for ultrasound endoscopy due to pathologies other than the biliopancreatic disease. The age range was 23-89, with a mean of 56.75 years. The most frequent history was steatosis or steatohepatitis (n = 14) (25.45 %). The most frequent indication for performing the procedure was subepithelial lesion (n = 29) (52.73 %). The percentages of patients according to pancreatic echogenicity were Grade I (n = 29) (52.73 %); Grade II (n = 5) (9.09 %); Grade III (n = 18) (32.73 %); Grade IV (n = 3) (5.45 %). Grades I and II were taken as a normal pancreas and Grades III and IV as a fatty pancreas, divided into n = 34 patients (61.82 %) for a normal pancreas and n = 21 (38 %) for a fatty pancreas. According to the scale used, there is a fatty pancreas prevalence of 38.18 %. The LFI was measured in three subgroups: those considered endoscopically normal, those classified as fatty pancreas, and patients diagnosed with pancreatic cancer confirmed by cytology taken from the pancreas. The LFI for these groups were, respectively, normal pancreas: LFI 2.60, range 0.97-3.47 (95 % CI 2.17-3.02); fatty pancreas: LFI 3.87, range 2-5.5 (95 % CI 3.44-4.29); pancreatic cancer: LFI 6.35, range 5.8-7.8 (95 % CI 5.92-6.77). Conclusions: This is the first pilot study that applies the LFI to the pancreatic parenchyma. It is useful in differentiating a normal pancreas, a fatty pancreas, and pancreatic carcinoma non-invasively. This finding must be validated in larger and more heterogeneous populations.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Pancreas , Pancreatic Neoplasms , Ultrasonics , Liver Cirrhosis , Pancreatic Diseases , Data Collection , Parenchymal Tissue
6.
Rev. venez. cir ; 75(1): 45-48, ene. 2022. ilus
Article in Spanish | LILACS, LIVECS | ID: biblio-1391723

ABSTRACT

Las neoplasias quísticas pancreáticas se observan en cuerpo y cola del páncreas en mujeres de mediana edad. Son consideradas lesiones premalignas y requieren extirpación quirúrgica según tamaño y características imagenológicas. El cistoadenoma mucinoso es una neoplasia epitelial que produce mucina, forma quistes que surgen del páncreas y puede progresar a carcinoma invasivo. Representan la mitad de las neoplasias quísticas del páncreas. Lesiones sintomáticas en pacientes operables deben resecarse. En caso de lesiones asintomáticas, es importante diferenciar su estirpe (serosa o mucinosa) y su riesgo de degeneración. Una vez valorado el paciente, se indica tratamiento quirúrgico u observación. Caso clínico: Paciente femenina de 43 años con antecedentes de hipertensión arterial sistémica e hipotiroidismo controlados, quien presenta cuadro clínico caracterizado por distensión abdominal y síntomas dispépticos. Se realiza ultrasonografía abdominal y tomografía de abdomen y pelvis con doble contraste evidenciándose lesión redondeada hipodensa en rango líquido con septos finos en su interior, definida, que impresiona formar parte de cuerpo y cola de páncreas. Se decide resolución quirúrgica mediante laparotomía exploradora. Informe histopatológico: cistoadenoma mucinoso cuerpo y cola de páncreas. Conclusión: Las neoplasias quísticas del páncreas son tumoraciones que en la actualidad gracias al desarrollo de nuevas tecnologías se observan en nuestra práctica médica con más frecuencia. Al sospechar una neoplasia quística del páncreas, el tratamiento adecuado es la resección quirúrgica adaptada a la localización del tumor. El manejo de esta patología debe ser individualizado de acuerdo a las características clínicas, imagenológicas e histopatológicas del mismo(AU)


Pancreatic cystic neoplasms are observed in the body and tail of the pancreas in middle-aged women. They are considered premalignant lesions and require surgical removal depending on their size and imaging characteristics. Mucinous cystadenoma is an epithelial neoplasm that produces mucin, forms cysts that arise from the pancreas, and can progress to invasive carcinoma. They represent half of the cystic neoplasms of the pancreas. Symptomatic lesions in operable patients should be resected. In the case of asymptomatic lesions, it is important to differentiate their type (serous or mucinous) and their risk of degeneration. Once the patient has been assessed, surgical treatment or observation is indicated. Clinical case: A 43-year-old female patient with a history of controlled systemic arterial hypertension and hypothyroidism, who presented a clinical picture characterized by abdominal distension and dyspeptic symptoms. Abdominal ultrasonography and tomography of the abdomen and pelvis with double contrast were performed, a rounded, hypodense lesion in the liquid range with fine septa inside, defined, which appears to be part of the body and tail of the pancreas. Surgical resolution was decided by exploratory laparotomy. Histopathological report: mucinous cystadenoma of the body and tail of the pancreas. Conclusion: Cystic neoplasms of the pancreas are tumors that today, thanks to the development of new technologies, are observed more frequently in our medical practice. When suspecting a cystic neoplasm of the pancreas, the appropriate treatment is surgical resection adapted to the location of the tumor. The management of this pathology must be individualized according to its clinical, imaging and histopathological characteristics(AU)


Subject(s)
Humans , Female , Adult , Pancreas , Pancreatic Neoplasms , Cystadenoma, Mucinous , Pancreatectomy , Hypertension , Hypothyroidism , Laparotomy
7.
Ann. afr. méd. (En ligne) ; 15(4): 1-8, 2022. figures, tables
Article in French | AIM | ID: biblio-1398398

ABSTRACT

Contexte et objectif. Le pancréas étant un organe profond, son exploration clinique est parfois limitée et peu performante. Le diagnostic de ces pathologies repose principalement sur le dosage des enzymes pancréatiques (la lipasémie notamment) et l'imagerie médicale. L'objectif de la présente étude était de décrire le profil scanographique des tumeurs pancréatiques. Méthodes. Il s'agissait d'une série des cas documentaires menée dans 3 Services de radiologie à Kinshasa de janvier 2016 à juin 2021, ayant retenu 86 comptes rendus de tomodensitométrie (TDM) abdominale des patients avec pathologie pancréatique. Toutes les images archivées ont été relues par spécialistes en imagerie. Résultats. 66 cas de tumeurs pancréatiques ont été colligés. Le sexe masculin était prépondérant (sex-ratio H/F=1,6) avec un âge moyen de 55,7 ± 14,7 ans (16 à 92 ans). Le syndrome de cholestase (50 %) et la douleur abdominale (épigastrique) étaient les indications les plus retrouvées. Les contours étaient lobulés dans plus de la moitié des cas (56,1 %). Le canal de Wirsung était dilaté dans la plupart des tumeurs. Les tumeurs étaient résécables dans 26 % des cas. Conclusion. La TDM abdominale contribue au diagnostic des pathologies pancréatiques. Elles affectent le plus souvent des sujets âgés du sexe masculin et sont dominées par les tumeurs qui sont généralement diagnostiquées au stade non-résécable


Context and objective. The pancreas being a deep organ, its clinical exploration is sometimes limited and inefficient. The diagnosis of pancreatic pathologies is mainly based on the dosage of pancreatic enzymes (lipasemia in particular) and medical imaging. The objective of the present study was to describe the scanographic profile of pancreatic tumors in 3 radiology departments in Kinshasa. Methods. It was a retrospective serial case study conducted in 3 radiology departments in Kinshasa from January 2016 to June 2021, having retained 86 reports of abdominal computed tomography (CT) scan of patients with pancreatic pathology. Results. 66 cases of pancreatic tumors were involved. Male patients were predominant (sex-ratio M/F=1.6) and the mean age of 55.7 ± 14.7 years (range: 16 to 92 years). Cholestasis syndrome (50 %) and abdominal (epigastric) pain were the most common indications. In tumors, the contours were lobulated (56.1 %). The Wirsung duct was dilated in most tumors. The tumors were resectable in 26 % of cases. Conclusion. The abdominal CT-scan contributes to the diagnosis of pancreatic pathologies. These pathologies mostly affect male elderly subjects, are predominantly tumoral and generally diagnosed in late unresectable stage.


Subject(s)
Humans , Male , Female , Pancreatic Neoplasms , Tomography, X-Ray Computed , Disease Progression , Diagnosis , Neoplasm Metastasis
8.
Chinese Journal of Surgery ; (12): 441-448, 2022.
Article in Chinese | WPRIM | ID: wpr-935619

ABSTRACT

Objective: To compare the outcomes of modified Appleby procedure and sub-adventitial divestment technique for locally advanced or borderline resectable pancreatic body cancer. Methods: A total of consecutive 58 patients(33 males and 25 females) who were diagnosed as locally advanced or borderline resectable pancreatic body cancer and underwent distal pancreatectomy at Pancreas Center, First Affiliated Hospital of Nanjing Medical University between September 2013 and May 2019 were retrospectively reviewed. The age(M(IQR)) was 62(9)years(range: 43 to 79 years). Thirty-one patients underwent distal pancreatectomy with celiac axis resection (DP-CAR) and 27 patients underwent distal pancreatectomy with sub-adventitial divestment technique(SDT). Perioperative parameters and follow-up data of these patients were analyzed. Quantitative data were compared with Wilcoxon test while categorical variables were compared with χ2 test or Fisher's exact test. Survival results were estimated by the Kaplan-Meier survival method with a Log-rank test. Results: There were no differences in age,gender,body mass index,abdominal symptoms,comorbidity or preoperative serum CA19-9 between two groups(all P>0.05). Obvious preoperative weight loss was more common in the group of SDT(48.1%(13/27) vs. 19.4%(6/31),χ²=5.431,P=0.020). Longer operative time(310(123) minutes vs. 254(137)minutes, Z=2.277,P=0.023),higher rate of combined organ resection(41.9%(13/31) vs. 14.8%(4/27),χ²=5.123,P=0.041) and longer postoperative hospital stay(15(10) days vs. 11(5)days,Z=2.292,P=0.022) were observed in the group of DP-CAR. Moreover,rate of overall morbidities was also higher (71.0%(22/31) vs. 29.6%(8/27),χ2=9.876,P=0.003),implicated by clinically relevant postoperative pancreatic fistula(61.3%(19/31) vs. 29.6%(8/27),χ2=5.814,P=0.020) in the DP-CAR group. Tumor size of the DP-CAR group was bigger(4.9(1.5)cm vs. 4.0(1.2)cm,Z=2.343,P=0.019) but no difference was seen between the DP-CAR group and SDT group in R0+R1(<1 mm) resection rate (84.0%(21/25) vs. 90.0%(18/20),P=0.678) and LNR(12.0(23.0)% vs. 9.0(18.0)%,Z=1.238,P=0.216),as well as median disease free survival(11.7 months vs. 11.4 months,Z=0.019,P=0.892) and median overall survival(16.3 months vs. 13.7 months,Z=0.172,P=0.679). Conclusions: Both DP-CAR and distal pancreatectomy with SDT are relatively safe and feasible for locally advanced or borderline resectable pancreatic body cancer. Compared with arterial resection,SDT may contribute to lower rates of postoperative complications and shorter duration of hospitalization,but no significant benefit is seen in long-term survival.


Subject(s)
Celiac Artery/surgery , Female , Humans , Male , Pancreatectomy/methods , Pancreatic Neoplasms/pathology , Postoperative Complications , Retrospective Studies
9.
Chinese Journal of Surgery ; (12): 134-139, 2022.
Article in Chinese | WPRIM | ID: wpr-935591

ABSTRACT

Objective: To evaluate the safety and feasibility of laparoscopic surgery after neoadjuvant chemotherapy for pancreatic cancer. Methods: Clinical data of 8 patients underwent laparoscopic surgery after neoadjuvant chemotherapy for pancreatic cancer at Fudan University Shanghai Cancer Center from September 2019 to June 2020 were reviewed retrospectively. There were 5 males and 3 females,aged from 47 to 72 years old. All patients underwent abdominal enhanced CT and PET-CT before operation to accurately evaluate the tumor stage and exclude distant metastasis. Results: Neoadjuvant chemotherapy with AG regimen(gemcitabine 1 000 mg/m2 and albumin bound paclitaxel 125 mg/m2) was received for 2 to 6 cycles before surgery. All 8 patients successfully completed the operation,including 5 cases of pancreaticoduodenectomy,2 cases of radical antegrade modular pancreatosplenectomy(RAMPS),and 1 case of total pancreatectomy. No conversion to laparotomy or laparoscopic assisted surgery. The operation time was 240 to 450 minutes,the blood loss was 100 to 500 ml,the postoperative length of stay was 10 to 16 days. During the follow-up period up to December 31, 2020, there was 1 case suffered grade B pancreatic leakage and abdominal infection. The numbers of resected lymph nodes were 9 to 31. All patients received R0 resection. The follow-up times were 4.5 to 9.5 months. One patient underwent RAMPS was diagnosed as liver metastasis after 2 months of the operation,and the other 7 patients still survived without tumor recurrence. Conclusion: Minimally invasive surgery of pancreatic cancer after neoadjuvant chemotherapy is safe and feasible in experienced pancreatic minimally invasive centers.


Subject(s)
Aged , China , Female , Humans , Laparoscopy , Male , Middle Aged , Neoadjuvant Therapy , Neoplasm Recurrence, Local , Pancreatectomy , Pancreatic Neoplasms/surgery , Positron Emission Tomography Computed Tomography , Retrospective Studies
10.
Chinese Journal of Surgery ; (12): 128-133, 2022.
Article in Chinese | WPRIM | ID: wpr-935590

ABSTRACT

Objective: To compare and analyze the clinical efficacy of pancreaticoduodenectomy for distal bile duct cancer and pancreatic head cancer. Methods: Clinical data of 1 005 patients who underwent pancreaticoduodenectomy and postoperative pathological examination confirmed the diagnosis of distal bile duct cancer and pancreatic head cancer at the Pancreas Center of the First Affiliated Hospital of Nanjing Medical University from January 2016 to December 2020 were analyzed retrospectively. There were 112 cases in the distal bile duct cancer group, 71 males and 41 females,with age (M(IQR)) of 65(15) years(range: 40 to 87 years); 893 cases in the pancreatic head cancer group, 534 males and 359 females,with age of 64(13)years(range: 16 to 91 years). The differences between clinicopathological characteristics and postoperative overall survival of the two groups were analyzed by χ2 test, Fisher's exact probability method, rank sum test or log-rank test, respectively. The difference in postoperative overall survival between the two groups was compared using Kaplan-Meier method after propensity score matching (1∶1). Results: Compared with the pancreatic head cancer group,the distal bile duct cancer group had shorter operative time (240.0(134.0) minutes vs. 261.0(97.0) minutes, Z=2.712, P=0.007),less proportion of combined venous resection (4.5% (5/112) vs. 19.4% (173/893), χ²=15.177,P<0.01),smaller tumor diameter (2.0(1.0) cm vs. 3.0(1.5) cm,Z=10.567,P<0.01),higher well/moderate differentiation ratio (51.4% (56/112) vs. 38.0% (337/893), χ²=7.328, P=0.007),fewer positive lymph nodes (0(1) vs. 1(3), Z=5.824, P<0.01),and higher R0 resection rate (77.7% (87/112) vs. 38.3%(342/893), χ²=64.399, P<0.01),but with a higher incidence of overall postoperative complications (50.0% (56/112) vs. 36.3% (324/892), χ²=7.913,P=0.005),postoperative pancreatic fistula (28.6% (32/112) vs. 13.9% (124/893), χ²=16.318,P<0.01),and postoperative abdominal infection (21.4% (24/112) vs. 8.6% (77/892), χ²=18.001,P<0.01). After propensity score matching, there was no statistical difference in postoperative overall survival time between patients in the distal bile duct cancer group and the pancreatic head cancer group (50.6 months vs. 35.1 months,Z=1.640,P=0.201),and multifactorial analysis showed that tumor site was not an independent risk factor affecting the prognosis of patients in both groups after matching (HR=0.73,95%CI:0.43 to 1.23,P=0.238). Conclusions: Patients with distal bile duct cancer are more likely to benefit from early diagnosis and surgical treatment than patients with pancreatic head cancer,but with a relative higher postoperative complication rates. The different tumor origin site is not an independent risk factor for prognosis of patients with distal bile duct cancer and pancreatic head cancer after propensity score matching.


Subject(s)
Bile Ducts , Female , Humans , Male , Pancreas , Pancreatic Neoplasms/surgery , Pancreaticoduodenectomy , Retrospective Studies , Treatment Outcome
11.
Chinese Journal of Surgery ; (12): 46-51, 2022.
Article in Chinese | WPRIM | ID: wpr-935578

ABSTRACT

Objective: To identify the risk factors of newly developed nonalcoholic fatty liver disease(NAFLD) after pancreaticoduodenectomy(PD). Methods: The clinical data of 130 patients who had undergone PD at Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School of Nanjing University from June 2018 to December 2020 were collected retrospectively. There were 74 males and 56 females, with age(M(IQR)) of 62(16) years (range: 22 to 84 years). Twenty-nine patients who developed NAFLD were divided into NAFLD group and 101 patients who did not suffer NAFLD were divided into no NAFLD group. Observation indications included:(1)preoperative demographics,intraoperative and postoperative characteristics; (2)the risk factors of newly developed NAFLD after PD. Count data were analyzed using χ2 test or Fisher's exact test. Measurement data were analyzed by student t test or Mann-Whitney U test. Multivariate analysis was performed using Logistic regression model with a stepwise forward approach. Results: All 130 patients successfully underwent PD and 29 cases(22.3%) developed NAFLD in 6 months after PD. The results of univariate analysis showed that gender,diabetic mellitus,the level of triglyceride preoperatively,and pancreatic ductal adenocarcinoma were the related factors of the development of NAFLD after PD(t=-2.655, χ²=4.563,U=-2.192,χ²=7.044;all P<0.05).Multivariate analysis revealed that gender,body mass index and pancreatic ductal adenocarcinoma were independent risk factors for the development of NAFLD after PD(OR=2.849,1.214,4.165,all P<0.05). Conclusion: Gender, body mass index and pancreatic ductal adenocarcinoma were independent risk factors for the development of NAFLD after PD.


Subject(s)
Female , Humans , Male , Non-alcoholic Fatty Liver Disease , Pancreatic Neoplasms/surgery , Pancreaticoduodenectomy/adverse effects , Retrospective Studies , Risk Factors
12.
Chinese Journal of Surgery ; (12): 39-45, 2022.
Article in Chinese | WPRIM | ID: wpr-935577

ABSTRACT

Objective: To examine the clinical effect of minimally invasive duodenum preserving pancreatic head resection(DPPHR) for benign and pre-malignant lesions of pancreatic head. Methods: The clinical data of patients with diagnosis of benign or pre-malignant pancreatic head tumor were retrospectively collected and analyzed,all of them underwent laparoscopic or robotic DPPHR between October 2015 and September 2021 at Division of Gastrointestinal and Pancreatic surgery,Zhejiang Provincial People's Hospital. Thirty-three patients were enrolled with 10 males and 23 females. The age(M(IQR)) was 54(32) years old(range: 11 to 77 years old) and the body mass index was 21.9(2.9)kg/m2(range: 18.1 to 30.1 kg/m2). The presenting symptoms included abdominal pain(n=12), Whipple triad(n=2), and asymptomatic(n=19). There were 7 patients with hypertension and 1 patient with diabetes mellitus. There were 19 patients who were diagnosed as American Society of Anesthesiologists class Ⅰ and 14 patients who were diagnosed as class Ⅱ. The student t test,U test, χ2 test or Fisher exact test was used to compare continuous data or categorized data,respectively. All the perioperative data and metabolic morbidity were analyzed and experiences on minimally invasive DPPHR were concluded. Results: Fourteen patients underwent laparoscopic DPPHR,while the rest of 19 patients received robotic DPPHR. Indocyanine green fluorescence imaging was used in 19 patients to guide operation. Five patients were performed pancreatico-gastrostomy and the rest 28 patients underwent pancreaticojejunostomy. Pathological outcomes confirmed 9 solid pseudo-papillary neoplasms, 9 intraductal papillary mucinous neoplasms, 7 serous cystic neoplasms, 6 pancreatic neuroendocrine tumors, 1 mucous cystic neoplasm, 1 chronic pancreatitis. The operative time was (309.4±50.3) minutes(range:180 to 420 minutes),and the blood loss was (97.9±48.3)ml(range:20 to 200 ml). Eighteen patients suffered from postoperative complications,including 3 patients experienced severe complications(Clavien-Dindo Grade ≥Ⅲ). Pancreatic fistula occurred in 16 patients,including 8 patients with biochemical leak,7 patients with grade B pancreatic fistula and 1 patient with grade C pancreatic fistula. No one suffered from the duodenal necrosis and none perioperative death was occurred. The length of hospital stay was 14(7) days (range:6 to 87 days). The follow-up was 22.6(24.5)months(range:2 to 74 months). None suffered from recurrence or metastasis. During the follow-up,all the patients were free of refractory cholangitis. Moreover,in the term of endocrine dysfunction,no postoperative new onset of diabetes mellitus were observed in the long-term follow-up. However,in the view of exocrine insufficiency,pancreatic exocrine insufficiency and non-alcoholic fatty liver disease (NAFLD) was complicated in 2 and 1 patient,respectively,with the supplement of pancreatic enzyme,steatorrhea and weight loss relieved,but NAFLD was awaited to be seen. Conclusions: Minimally invasive DPPHR is feasible and safe for benign or pre-malignant lesions of pancreatic head. Moreover,it is oncological equivalent to pancreaticoduodenectomy with preservation of metabolic function without refractory cholangitis.


Subject(s)
Adolescent , Adult , Aged , Child , Duodenum/surgery , Female , Humans , Male , Middle Aged , Pancreas/surgery , Pancreatectomy , Pancreatic Neoplasms/surgery , Pancreaticoduodenectomy , Postoperative Complications , Retrospective Studies , Young Adult
13.
Chinese Journal of Surgery ; (12): 27-31, 2022.
Article in Chinese | WPRIM | ID: wpr-935575

ABSTRACT

When abdominal neoplasms originating from the pancreas or nearby organs locally involving the superior mesenteric artery (SMA), complete resection is still the only hope for cure. However, SMA resection and reconstruction is a complex surgical procedure associated with high postoperative morbidity and mortality. Intestinal autotransplantation has recently emerged in clinical practice as a treatment option for selected patients with neoplasms involving the SMA. The original procedure involved en bloc removal of a tumor together with the intestine, ex vivo resection and reconstruction of gastrointestinal tract by an intestinal autograft. To further refine this complex procedure, a modified method was developed in which a segmental bowel autograft is selected and harvested first during the initial stage of the operation, and radical resection of the neoplasm is carried out thereafter. The modification would better protect a healthy bowel autograft from potential damage due to prolonged warm ischemia and allow the subsequent lengthy process of dissection to be performed in an unrushed manner. Furthermore, this alteration would better adhere to the general principles of minimal tumor manipulation during operation and potentially decrease the risks of tumor implantation during in vitro organ perfusion. Although intestinal autotransplantation has expanded eligibility for resection of otherwise unresectable lesions involving the SMA, its operative complexity, high risks, and post-operative complications largely limit its clinical applications.


Subject(s)
Humans , Intestines , Mesenteric Artery, Superior/surgery , Pancreatic Neoplasms , Transplantation, Autologous
14.
Chinese Journal of Surgery ; (12): 22-26, 2022.
Article in Chinese | WPRIM | ID: wpr-935574

ABSTRACT

Pancreatic cancer is a malignant tumor with very poor prognosis. In the past decade, the surgical technique has made significant progress, but it has not brought desired effect in improving the survival outcome of pancreatic cancer patients. With the development of the concept of cancer treatment and the emergence of precision medicine, the surgical centered multidisciplinary treatment and collaborative diagnosis and treatment mode has gradually become the mainstream. Accurate preoperative assessment of pancreatic cancer has become a breakthrough for further improving the prognosis of patients with pancreatic cancer. From the perspective of precise assessment, this paper mainly summarized the status and progress on the following four aspects: the preoperative diagnosis and staging, the resectability evaluation, the neoadjuvant therapy strategy and efficacy evaluation of neoadjuvant therapy in pancreatic cancer, and also discussed the shortcomings and challenges in the field of precise assessment, finally in order to make the preoperative assessment of pancreatic cancer more precise and standard, and to provide useful reference for future research work.


Subject(s)
Humans , Neoadjuvant Therapy , Neoplasm Staging , Pancreatic Neoplasms/surgery , Prognosis
15.
Chinese Journal of Surgery ; (12): 10-16, 2022.
Article in Chinese | WPRIM | ID: wpr-935572

ABSTRACT

Pancreatic cancer is one of the most malignant digestive system tumors. In the recent decade, the effect of diagnosis and treatment of pancreatic cancer has improved due to the renewal of treatment concept and the popularization of effective treatment. However, the overall efficacy of pancreatic cancer is still dismal and the 5-year survival rate is only about 10%. Further improving the diagnosis and treatment of pancreatic cancer is the top priority of oncology research and clinical practice. Based on past clinical and scientific research experience, the authors have proposed ten hot spots and future directions for a reference, which focusing on early prevention, early diagnosis, and early treatment of pancreatic cancer, molecular typing and precise treatment, new drug development and regimen combination, surgical technology and strategy change, model establishment and database development, as well as innovation of traditional Chinese medicine and breakthrough of treatment concept. A breakthrough in the diagnosis and treatment of pancreatic cancer in the next ten years is raising hope, when doctors can truly prevent and control pancreatic cancer.


Subject(s)
Humans , Pancreatic Neoplasms/therapy , Treatment Outcome
16.
Chinese Journal of Pathology ; (12): 419-424, 2022.
Article in Chinese | WPRIM | ID: wpr-935556

ABSTRACT

Objective: To investigate the tumor immunity-related pathologic features and clinical significance in pancreatic ductal adenocarcinoma (PDAC). Methods: All pathologic materials and clinical information of 192 PDAC patients from the Cancer Hospital of the University of Chinese Academy of Sciences from January 2010 to December 2020 were collected. The onco-immune microenvironment associated morphologic features were evaluated, and MHC-Ⅰ, PD-L1, CD3, and CD8 expression were detected by immunohistochemistry (IHC). Then the correlation between the factors and their influence on prognosis was analyzed. Results: There were 163 cases of non-specific adenocarcinoma (163/192, 84.90%), 18 cases of adeno-squamous carcinoma (18/192, 9.37%), and 11 cases of other rare subtypes (11/192, 5.73%). Perineural invasion was observed in 110 cases (110/192, 57.29%) and vascular invasion in 86 cases (86/192, 44.79%). There were 84 cases (84/182, 46.15%) with severe chronic inflammation. Tumor infiltrating immune cell numbers (TII-N) were increased in 52 cases (52/192, 27.08%). Lymphocytes and plasma cells were the main infiltrating immune cells in 60 cases (60/192, 31.25%), whereas in 34 cases (34/192, 17.71%) the tumors were mainly infiltrated by granulocytes, and 98 cases (98/192, 51.04%) showed mixed infiltration. CD3+T cells were deficient in 124 cases (124/192, 66.31%). CD8+T cells were deficient in 152 cases (152/192, 79.58%). MHC-Ⅰ expression was down-regulated in 156 cases (156/192, 81.25%), and PD-L1 was positive (CPS≥1) in 46 cases (46/192, 23.96%). Statistical analysis showed that TII-N was negatively correlated with vascular invasion (P=0.035), perineural invasion (P=0.002), stage (P=0.004) and long-term alcohol consumption (P=0.039). The type of immune cells correlated positively with chronic pancreatic inflammation (P=0.002), and negatively with tumor differentiation (P=0.024). CD8+T cells were positively correlated with CD3+T cells (P=0.032), MHC-Ⅰ expression (P<0.001) and PD-L1 expression (P=0.001), and negatively correlated with long-term smoking (P=0.016). Univariate analysis showed that histological nonspecific type (P=0.013) and TII-N (P<0.001) were the factors for good prognosis. Vascular invasion (P=0.032), perineural invasion (P=0.001), high stage (P=0.003) and long-term alcohol consumption (P=0.004) were adverse prognostic factors. COX multivariate risk analysis found that TII-N was an independent favorable factor for PDAC, while perineural invasion was an independent adverse risk factor. Conclusions: TII-N is an independent superior prognostic factor for PDAC, and significantly correlated with many factors; chronic alcohol consumption and smoking may inhibit onco-immunity in PDAC patients.


Subject(s)
Adenocarcinoma/pathology , B7-H1 Antigen/metabolism , Biomarkers, Tumor/metabolism , Carcinoma, Pancreatic Ductal/pathology , Humans , Inflammation/pathology , Lymphocytes, Tumor-Infiltrating/metabolism , Pancreatic Neoplasms/pathology , Prognosis , Tumor Microenvironment
17.
Article in Chinese | WPRIM | ID: wpr-927883

ABSTRACT

As the detection rate of pancreatic cystic neoplasms (PCN) increases,recommendations or guidelines for the diagnosis and treatment of PCN have been released from professional organizations.From the perspective of radiology,we compared seven guidelines in terms of general introduction,preoperative monitoring methods and strategies,stratification of risk factors,surgical indications,and postoperative follow-ups,aiming to provide references for the evaluation of images and the formulation of individualized approach for the treatment of PCN.


Subject(s)
Humans , Pancreatic Cyst/therapy , Pancreatic Neoplasms/therapy , Pregnenolone Carbonitrile , Radiography , Radiology
18.
Rev. cuba. invest. bioméd ; 41: e2408, 2022. ilus, tab
Article in Spanish | LILACS, CUMED | ID: biblio-1408602

ABSTRACT

Introducción: El índice pronóstico nutricional es un marcador inmuno-nutricional que puede ser útil como factor pronóstico en tumores gastrointestinales. Objetivo: Evaluar supervivencia de pacientes con adenocarcinoma pancreático avanzado tratados con quimioinmunoterapia según índice pronóstico nutricional, según parámetros clínico-patológicos y tratamiento. Métodos: Se realizó estudio retrospectivo y observacional en pacientes que recibieron quimioterapia gemcitabina-oxaliplatino combinado a nimotuzumab (n=118), en el Hospital Ameijeiras, entre 2014 y 2019. Se evaluó supervivencia por método Kaplan-Meier, y regresión de Cox, para determinar los factores pronósticos independientes de supervivencia. Resultados: El punto de corte seleccionado fue 40 (sensibilidad 52,9 por ciento y especificidad 85,7 por ciento (p = 0,019), con área bajo la curva de 0,693. Para pacientes con índice menor de 40, la supervivencia fue más baja respecto a los pacientes con índice ≥ 40 (11,4 meses frente a 16,0 meses; p=0,001), con un HR de 1,7 (1,13-2,60; p=0,011). Las variables mayormente asociadas con índice pronóstico nutricional altos son pacientes con sesenta años o menos; ECOG cero, índice de masa corporal ≥25 Kg/m2 y albúmina sérica >3,5g/dL (x² < 0,05). Los pacientes con índice ≥ 40 tienen medianas de supervivencia más altas que pacientes con índice < 40 en las variables seleccionadas con p < 0,05, excepto el índice de masa corporal. Conclusiones: Este trabajo constituye el primer reporte nacional de utilización del índice pronóstico nutricional como pronóstico de supervivencia en pacientes con cáncer de páncreas avanzado(AU)


Background: The nutritional prognostic index is an immuno-nutritional marker that can be useful as a prognostic factor in gastrointestinal tumors. Aim: To evaluate the survival of patients with advanced pancreatic adenocarcinoma treated with chemoimmunotherapy according to the nutritional prognostic index, according to clinical-pathological parameters and treatment. Methods: A retrospective and observational study was carried out in patients who received gemcitabine-oxaliplatin chemotherapy combined with nimotuzumab (n=118), at the Ameijeiras Hospital, between 2014 and 2019. Survival was evaluated by the Kaplan-Meier method, and Cox regression, for determine independent prognostic factors for survival. Results: The selected cut-off point was 40 (52.9 percent sensitivity and 85.7 percent specificity) (p=0,019), with an area under the curve of 0,693. For patients with an index less than 40, survival was lower compared to patients with index ≥ 40 (11, 4 months vs. 16, 0 months; p=0,001), with a HR of 1, 7 (1, 13-2, 60; p=0,011). The variables mostly associated with nutritional prognostic index patients with 60 years or less, ECOG 0, body mass index ≥ 25 kg/m2 and serum albumin >3,5g/dL (x2 < 0, 05). Patients with index ≥ 40 have higher median survival than patients with index < 40 in the selected variables with p < 0, 05, except body mass index. Conclusions: This work constitutes the first national report on the use of the nutritional prognostic index as a prognosis of survival in patients with advanced pancreatic cancer(AU)


Subject(s)
Humans , Middle Aged , Pancreatic Neoplasms/diagnosis , Nutrition Assessment , Cancer Survivors , Oxaliplatin/therapeutic use , Gemcitabine/therapeutic use , Antineoplastic Agents/therapeutic use , Retrospective Studies , Longitudinal Studies , Observational Study
19.
Vaccimonitor (La Habana, Print) ; 30(3)2021. tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1341783

ABSTRACT

Se realizó un estudio retrospectivo y observacional en pacientes con adenocarcinoma pancreático avanzado, tratados con Nimotuzumab combinado con un esquema de quimioterapia GEMOX, atendidos en el Servicio de Oncología Clínica del Hospital Clínico Quirúrgico Hermanos Ameijeiras entre 2013 y 2019 (n=118), cuyo objetivo fue evaluar la respuesta al tratamiento y la supervivencia global según variables clínicas, histopatológicas y tratamiento. Se utilizó método chi-cuadrado para la asociación de variables. Se evaluó la supervivencia global por el método de Kaplan Meier y se utilizó la prueba de Log-Rank y Breslow para la comparación de las curvas, con valor p<0.05. La tasa de control de la enfermedad fue 44,9. La mediana de supervivencia fue de 13,8 meses (IC95 por ciento:11,7-15,8). Las variables estadísticamente significativas asociadas con mayor respuesta al tratamiento y supervivencia fueron: no hábitos tabáquicos; índice plaquetas-linfocitos por debajo de 200; tumores primarios T2-T3, de localización predominantemente en cabeza pancreática; no presencia de metástasis al diagnóstico y más de seis dosis de quimioterapia o Nimotuzumab. Los pacientes con clasificación de bajo peso y albúmina sérica baja tuvieron peor supervivencia (p<0.05). En 42 pacientes se realizó una segunda línea de quimioterapia y se obtuvo supervivencia de 17,4 meses (IC95 por ciento:13,5-21,4). Las toxicidades clasificadas como grado 3-4 se reportaron en 27 pacientes (22,9 por ciento), las más frecuentemente observadas fueron: neuropatía (14,4 por ciento), neutropenia (10,2 por ciento) y trombopenia (9,3 por ciento). En condiciones de práctica clínica, con el Nimotuzumab combinado con quimioterapia GEMOX se obtuvieron óptimas tasas de control de la enfermedad y supervivencia con buen perfil de seguridad(AU)


A retrospective and observational study was carried out in patients with advanced pancreatic adenocarcinoma, treated with Nimotuzumab combined with a GEMOX chemotherapy scheme, in the Clinical Oncology Service at the Ameijeiras Hospital, between 2013 and 2019 (n =118), whose objective was to evaluate the response to the treatment and overall survival according to clinical, histopathological and treatment variables. The chi-square method was used for the association of variables. Overall survival was evaluated by the Kaplan Meier method and the Log-Rank and Breslow test for the comparison of the curves, with p <0.05. The disease control rate was 44.9. The median survival was 13.8 months (95 percent CI: 11.7-15.8). The statistically significant variables associated with greater response to treatment and survival were: no smoking habits; platelet-lymphocyte index below 200; T2-T3 primary tumors, predominantly located in the pancreatic head; no presence of metastases at diagnosis and greater than six doses of chemotherapy and Nimotuzumab. Patients classified as underweight and low serum albumin had worse survival (p <0.05). Second-line chemotherapy was performed in 42 patients and it was obtained SV of 17.4 months (95 percent CI: 13.5-21.4). Toxicities classified as grade 3-4 were reported in 27 patients (22.9 percent); the most frequently observed were: neuropathy (14.4 percent), neutropenia (10.2 perrcent) and thrombopenia (9.3 percent). Under clinical practice conditions, Nimotuzumab combined with GEMOX chemotherapy obtained optimal disease control and survival rates with a good safety profile(AU)


Subject(s)
Humans , Male , Female , Pancreatic Neoplasms/drug therapy , Reference Drugs , Retrospective Studies , Observational Study , Antineoplastic Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL